11 Best Performing Long Term Stocks According to Analysts

Page 5 of 10

6. Ocular Therapeutix, Inc. (NASDAQ:OCUL)

5-year Revenue Growth Rate: 50.81%

Year-To-Date Performance: 38.44%

Number of Hedge Fund Holders: 27

Analysts Upside Potential: 40.50%

Ocular Therapeutix, Inc. (NASDAQ:OCUL) is one of the Best Performing Long Term Stocks According to Analysts. On September 15, Daniil Gataulin from Chardan Capital initiated Ocular Therapeutix, Inc. (NASDAQ:OCUL) with a Buy rating and a $21 price target.

The analyst highlighted the company’s Axpaxli program, which is the company’s lead program and is being gradually launched over several months. Axpaxli aims to reduce the treatment burden for patients who need frequent anti-VEGF injections. These injections are commonly used for wet age-related macular degeneration and non-proliferative diabetic retinopathy. The analyst believes Axpaxli has significant potential to improve patient outcomes by lowering how often treatments are required. Gataulin suggests that this could make it a valuable option in the eye care market and the gradual release strategy allows Ocular Therapeutix, Inc. (NASDAQ:OCUL) to manage supply and uptake effectively.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on eye diseases. It develops sustained-release drug treatments using its ELUTYX hydrogel technology.

Page 5 of 10